Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-09-11 18:36:49 ET · period of report 2026-09-09 · accession 0001193125-26-389512 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-11 18:36 | 2026-09-09 | ARTV | Horan Christopher | Chief Tech Ops Off | A - Grant | $0.00 | +40.0K | 323.1K | +14% | $0 |
| D | 2026-09-11 18:36 | 2026-09-09 | ARTV | Horan Christopher | Chief Tech Ops Off | A - Grant | $0.00 | +120.0K | 120.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-09 | A | A | 40,000 | $0.00 | 323,084 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2026-09-09 | A | A | 120,000 | $0.00 | 120,000 | D | $10.79 · — to 2036-09-08 | 120,000 Common Stock | (F2) Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. |